18F-FDG PET/CT biomarkers as predictors of long term outcomes and survival rates in patients with high risk malignant pulmonary masses/nodules treated with stereotactic ablative radiotherapy

Raef R. Boktor,Salvatore U. Berlangieri,Eddie Lau,Adeline Lim,Sylvia J. Gong,Xia Li,Andrew M. Scott
DOI: https://doi.org/10.1007/s12149-024-01983-9
2024-09-30
Annals of Nuclear Medicine
Abstract:Stereotactic ablative body radiotherapy (SABR) is a standard treatment option for patients with malignant pulmonary masses (including primary and metastatic lesions) who are unfit for surgery or who are medically operable but refuse surgery. Flourine-18 flurodeoxyglucose positron emission tomography ( 18 F-FDG PET) volumetric metabolic parameters, i.e., metabolic tumour volume (MTV) and total lesion glycolysis (TLG) play an important role in assessing the biological characteristics of some tumours and its role as potential prognostic factors has also been introduced.
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?